Tenofovir alafenamide fumarateProduct ingredient for Tenofovir alafenamide

Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil.¹ Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion.⁸ Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration.² It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.⁶ Tenofovir alafenamide is indicated to treat chronic hepatitis B,⁹ treat HIV-1,^11,12,13,14 and prevent HIV-1 infections.^11,17

Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.¹⁰